Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer.
Aged
Aged, 80 and over
Animals
Autophagy
/ drug effects
Cell Proliferation
/ drug effects
Digoxin
/ therapeutic use
Female
Humans
Iodine Radioisotopes
/ therapeutic use
Male
Mice
Radiation Tolerance
/ drug effects
Radiation-Sensitizing Agents
/ therapeutic use
Thyroid Cancer, Papillary
/ therapy
Thyroid Neoplasms
/ therapy
Autophagy
Digoxin
Non‐medullary thyroid cancer
Radioactive iodide
Redifferentiation
Journal
Cellular oncology (Dordrecht)
ISSN: 2211-3436
Titre abrégé: Cell Oncol (Dordr)
Pays: Netherlands
ID NLM: 101552938
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
10
12
2019
accepted:
13
01
2021
revised:
09
01
2021
pubmed:
4
2
2021
medline:
15
12
2021
entrez:
3
2
2021
Statut:
ppublish
Résumé
Non-medullary thyroid cancer (NMTC) treatment is based on the ability of thyroid follicular cells to accumulate radioactive iodide (RAI). However, in a subset of NMTC patients tumor dedifferentiation occurs, leading to RAI resistance. Digoxin has been demonstrated to restore iodide uptake capacity in vitro in poorly differentiated and anaplastic NMTC cells, termed redifferentiation. The aim of the present study was to investigate the in vivo effects of digoxin in TPO-Cre/LSL-Braf Mice with thyroid cancer were subjected to 3D ultrasound for monitoring tumor growth and We found that in mice, tumor growth was inhibited and These in vivo data support the hypothesis that digoxin may represent a repositioned adjunctive treatment modality that suppresses tumor growth and improves RAI sensitivity in patients with RAI-refractory NMTC.
Identifiants
pubmed: 33534128
doi: 10.1007/s13402-021-00588-y
pii: 10.1007/s13402-021-00588-y
pmc: PMC8213564
doi:
Substances chimiques
Iodine Radioisotopes
0
Iodine-124
0
Radiation-Sensitizing Agents
0
Digoxin
73K4184T59
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
611-625Subventions
Organisme : Cancer Research UK
ID : 13083
Pays : United Kingdom
Organisme : KWF Kankerbestrijding
ID : KUN2014-6728
Organisme : Nederlandse Organisatie voor Wetenschappelijk Onderzoek
ID : NWO; 016.136.065
Références
Acta Oncol. 2018 Jan;57(1):120-128
pubmed: 29202630
Cancer Res. 2008 Aug 15;68(16):6688-97
pubmed: 18701493
Crit Rev Oncol Hematol. 2020 Jan;145:102822
pubmed: 31911396
J Clin Invest. 2016 Nov 1;126(11):4119-4124
pubmed: 27669459
Nat Cell Biol. 2015 Mar;17(3):288-99
pubmed: 25720963
Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1804-7
pubmed: 26364159
J Mol Endocrinol. 2017 Nov;59(4):R141-R154
pubmed: 28931558
Eur J Cancer. 2010 Jan;46(2):395-404
pubmed: 19811904
Clin Cancer Res. 2009 Apr 15;15(8):2583-7
pubmed: 19351775
PLoS Genet. 2016 Aug 05;12(8):e1006239
pubmed: 27494611
Expert Opin Ther Targets. 2007 Aug;11(8):1043-53
pubmed: 17665977
Cell. 2014 Oct 23;159(3):676-90
pubmed: 25417114
PLoS One. 2017 Jun 7;12(6):e0178611
pubmed: 28591151
ACS Chem Biol. 2013 Dec 20;8(12):2724-2733
pubmed: 24168452
Mol Cancer Ther. 2017 Jan;16(1):169-181
pubmed: 27837029
J Clin Invest. 2016 Mar 1;126(3):1052-66
pubmed: 26878173
Clin Transl Sci. 2012 Feb;5(1):39-42
pubmed: 22376255
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1615-20
pubmed: 21220306
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19579-86
pubmed: 19020076
Front Physiol. 2013 Oct 02;4:272
pubmed: 24106480
Nat Rev Cancer. 2013 Mar;13(3):184-99
pubmed: 23429735
Clin Cancer Res. 2015 Mar 1;21(5):1028-35
pubmed: 25549723
Cancer Res. 2009 Apr 1;69(7):2739-47
pubmed: 19293189
Trends Cardiovasc Med. 2016 Oct;26(7):585-95
pubmed: 27156593
Ann Oncol. 2012 Oct;23 Suppl 7:vii110-9
pubmed: 22997443
J Clin Endocrinol Metab. 2019 May 1;104(5):1417-1428
pubmed: 30256977
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
Nat Protoc. 2012 Mar 01;7(3):562-78
pubmed: 22383036
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Oncotarget. 2017 Jul 4;8(27):44203-44216
pubmed: 28496002
Endocr Rev. 2019 Dec 1;40(6):1573-1604
pubmed: 31322645
N Engl J Med. 2016 Dec 8;375(23):2307
pubmed: 27959677
Gynecol Oncol. 2016 Feb;140(2):285-8
pubmed: 26691221
Oncotarget. 2017 May 23;8(21):34727-34735
pubmed: 28423729
Histopathology. 2016 Sep;69(3):406-22
pubmed: 26802460
J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9
pubmed: 16684830
Lancet. 2014 Jul 26;384(9940):319-28
pubmed: 24768112
J Surg Oncol. 2014 Sep;110(4):375-82
pubmed: 24961938
Biochemistry. 1988 Nov 1;27(22):8400-8
pubmed: 2853965
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
Mol Cell. 2007 Jan 26;25(2):193-205
pubmed: 17244528
Autophagy. 2016 Jul 2;12(7):1195-205
pubmed: 27105307
Mol Endocrinol. 2004 Nov;18(11):2817-29
pubmed: 15319451
Nature. 2011 Apr 28;472(7344):486-90
pubmed: 21441909
Br J Cancer. 2016 Nov 22;115(11):1289-1295
pubmed: 27755533
Cancer Res. 1986 Dec;46(12 Pt 1):6059-63
pubmed: 3465433
Neuron. 1990 Apr;4(4):571-82
pubmed: 2157471
J Mol Diagn. 2016 Nov;18(6):851-863
pubmed: 27637301
N Engl J Med. 2013 Feb 14;368(7):623-32
pubmed: 23406027
Circulation. 2000 Nov 14;102(20 Suppl 4):IV69-74
pubmed: 11080134
Endocr Relat Cancer. 2013 Dec 16;21(1):R13-29
pubmed: 24163390
Nat Rev Drug Discov. 2008 Nov;7(11):926-35
pubmed: 18948999
J Nucl Med. 2018 May;59(5):780-786
pubmed: 29242405
J Biol Chem. 2015 Jul 3;290(27):16653-64
pubmed: 25971970
Sci Transl Med. 2012 Jul 18;4(143):143ra99
pubmed: 22814852
Circulation. 2004 Jun 22;109(24):2942-6
pubmed: 15210610
Eur J Endocrinol. 2015 Sep;173(3):399-408
pubmed: 26104753